Trevi Therapeutics, Inc. (TRVI) Operating Income (Loss) USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Trevi Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2024.
  • Trevi Therapeutics, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$11.9 M, a 57.4% decline year-over-year.
  • Trevi Therapeutics, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$38.3 M, a 25.7% decline year-over-year.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$33.9 M, a 13.4% decline from 2022.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$29.9 M, a 7.91% increase from 2021.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$32.5 M, a 0.04% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$38.3 M -$11.9 M -$4.34 M -57.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$33.9 M -$8.93 M -$2.28 M -34.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-20
Q3 2023 -$31.6 M -$9.05 M -$640 K -7.62% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$31 M -$8.38 M -$562 K -7.19% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$30.4 M -$7.56 M -$538 K -7.66% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$29.9 M -$6.66 M +$1.62 M +19.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$31.5 M -$8.41 M -$1.46 M -21% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$30.1 M -$7.82 M +$1.35 M +14.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$31.4 M -$7.03 M +$1.06 M +13.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$32.5 M -$8.27 M +$920 K +10% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$33.4 M -$6.95 M +$297 K +4.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$33.7 M -$9.17 M -$1.75 M -23.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$31.9 M -$8.09 M +$550 K +6.37% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$32.5 M -$9.19 M -$2.43 M -35.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$30.1 M -$7.24 M +$406 K +5.31% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$30.5 M -$7.41 M +$4 K +0.05% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$30.5 M -$8.64 M -$3.83 M -79.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$26.6 M -$6.77 M -$837 K -14.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$25.8 M -$7.65 M -$2.69 M -54.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$23.1 M -$7.42 M -$3.04 M -69.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$20.1 M -$4.81 M -$1.67 M -53.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$18.4 M -$5.93 M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$4.96 M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$4.38 M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$3.14 M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.